The ‘gouge factor’: Big companies want transparency in drug price negotiations
(By Ed Silverman for STAT) The path that prescription drugs take from the lab to your medicine chest is a
Read More(By Ed Silverman for STAT) The path that prescription drugs take from the lab to your medicine chest is a
Read More(By Sydney Lupkin for Kaiser Health News) Research released Monday finds comparable safety and efficacy for one type of biosimilar
Read More(By Ed Silverman for STAT) Many Americans appear to be misusing their prescription drugs in ways that put their health
Read More(By Julie Appleby for Kaiser Health News) In one of the first looks at privately insured patients with opioid problems,
Read More(By Sharon Begley for STAT) In the wake of disappointing results this week for yet another experimental Alzheimer’s drug, scientists who
Read More(By Eric Boodman for STAT) The herbal supplement seemed like a miracle. Trying to kick an opioid addiction, the middle-aged
Read More(By Dylan Scott for STAT) PHILADELPHIA — The drug industry didn’t really feel the heat here at the Democratic National
Read More(By Ed Silverman for STAT) Faced with budgetary constraints, England’s National Health Service took several controversial steps to delay coverage
Read More(By Andrew Joseph for STAT) Several teams of scientists are racing to develop a vaccine for the Zika virus. But
Read MoreThe Food and Drug Administration approved Probuphine (used in treatment of drug additions) under the condition that physicians are trained
Read More